Hisamitsu Pharmaceutical Co Stock Earnings Per Share
| HPX Stock | EUR 25.20 0.20 0.80% |
Hisamitsu Pharmaceutical Co fundamentals help investors to digest information that contributes to Hisamitsu Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Hisamitsu Stock. The fundamental analysis module provides a way to measure Hisamitsu Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hisamitsu Pharmaceutical stock.
Hisamitsu |
Hisamitsu Pharmaceutical Co Company Earnings Per Share Analysis
Hisamitsu Pharmaceutical's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Hisamitsu Pharmaceutical Earnings Per Share | 0.96 X |
Most of Hisamitsu Pharmaceutical's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hisamitsu Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
According to the company disclosure, Hisamitsu Pharmaceutical Co has an Earnings Per Share of 0.96 times. This is 88.53% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The earnings per share for all Germany stocks is 69.23% higher than that of the company.
Hisamitsu Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hisamitsu Pharmaceutical's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hisamitsu Pharmaceutical could also be used in its relative valuation, which is a method of valuing Hisamitsu Pharmaceutical by comparing valuation metrics of similar companies.Hisamitsu Pharmaceutical is rated # 2 in earnings per share category among its peers.
Hisamitsu Fundamentals
| Return On Equity | 0.0504 | |||
| Return On Asset | 0.0212 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 1.09 B | |||
| Shares Outstanding | 79.53 M | |||
| Shares Owned By Insiders | 26.45 % | |||
| Shares Owned By Institutions | 35.29 % | |||
| Price To Earning | 34.35 X | |||
| Price To Book | 1.14 X | |||
| Price To Sales | 0.02 X | |||
| Revenue | 120.19 B | |||
| Gross Profit | 70.07 B | |||
| EBITDA | 17.3 B | |||
| Net Income | 9.66 B | |||
| Cash And Equivalents | 143.16 B | |||
| Total Debt | 219 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 7.41 X | |||
| Book Value Per Share | 3,393 X | |||
| Cash Flow From Operations | 19.2 B | |||
| Earnings Per Share | 0.96 X | |||
| Number Of Employees | 2.78 K | |||
| Beta | 0.51 | |||
| Market Capitalization | 2.02 B | |||
| Total Asset | 302.86 B | |||
| Z Score | 5.4 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 1.49 % | |||
| Net Asset | 302.86 B | |||
| Last Dividend Paid | 42.0 |
About Hisamitsu Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hisamitsu Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hisamitsu Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hisamitsu Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Hisamitsu Stock
Hisamitsu Pharmaceutical financial ratios help investors to determine whether Hisamitsu Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hisamitsu with respect to the benefits of owning Hisamitsu Pharmaceutical security.